These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 25279663)
21. Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. Inoue S; Hashiguchi M; Takagi K; Kawai S; Mochizuki M Yakugaku Zasshi; 2009 Jul; 129(7):843-9. PubMed ID: 19571519 [TBL] [Abstract][Full Text] [Related]
22. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994 [TBL] [Abstract][Full Text] [Related]
23. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356 [TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Urano W; Taniguchi A; Yamanaka H; Tanaka E; Nakajima H; Matsuda Y; Akama H; Kitamura Y; Kamatani N Pharmacogenetics; 2002 Apr; 12(3):183-90. PubMed ID: 11927833 [TBL] [Abstract][Full Text] [Related]
25. Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients. Chaabane S; Messedi M; Akrout R; Ben Hamad M; Turki M; Marzouk S; Keskes L; Bahloul Z; Rebai A; Ayedi F; Maalej A Inflamm Res; 2018 Aug; 67(8):703-710. PubMed ID: 29796841 [TBL] [Abstract][Full Text] [Related]
26. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Hughes LB; Beasley TM; Patel H; Tiwari HK; Morgan SL; Baggott JE; Saag KG; McNicholl J; Moreland LW; Alarcón GS; Bridges SL Ann Rheum Dis; 2006 Sep; 65(9):1213-8. PubMed ID: 16439441 [TBL] [Abstract][Full Text] [Related]
27. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Lima A; Bernardes M; Azevedo R; Seabra V; Medeiros R Pharmacogenomics; 2016 Oct; 17(15):1649-1674. PubMed ID: 27676277 [TBL] [Abstract][Full Text] [Related]
28. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Lima A; Monteiro J; Bernardes M; Sousa H; Azevedo R; Seabra V; Medeiros R Biomed Res Int; 2014; 2014():368681. PubMed ID: 24967362 [TBL] [Abstract][Full Text] [Related]
29. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Cáliz R; del Amo J; Balsa A; Blanco F; Silva L; Sanmarti R; Martínez FG; Collado MD; Ramirez Mdel C; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Andreu JL; Graell E; Simon L; Martínez A; Mulero J Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028 [TBL] [Abstract][Full Text] [Related]
30. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981 [TBL] [Abstract][Full Text] [Related]
31. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate. Kotrych D; Dziedziejko V; Safranow K; Pawlik A Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725 [TBL] [Abstract][Full Text] [Related]
32. Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Qiu Q; Huang J; Shu X; Fan H; Zhou Y; Xiao C Sci Rep; 2017 Mar; 7():44015. PubMed ID: 28266606 [TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Lima A; Bernardes M; Azevedo R; Medeiros R; Seabra V Int J Mol Sci; 2015 Jun; 16(6):13760-80. PubMed ID: 26086825 [TBL] [Abstract][Full Text] [Related]
34. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis. Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001 [TBL] [Abstract][Full Text] [Related]
35. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Lee YH; Bae SC Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764 [TBL] [Abstract][Full Text] [Related]
36. Analysis of association of ADORA Grk M; Milic V; Dolzan V; Maksimovic N; Damnjanovic T; Pjevic MD; Pesic M; Novakovic I; Jekic B Pharmacogenomics J; 2020 Dec; 20(6):784-791. PubMed ID: 32448869 [TBL] [Abstract][Full Text] [Related]
37. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project. Uribarri M; Ruiz-Larrañaga O; Arteta D; Hernández L; Alcaro MC; Martínez A; Escorza-Treviño S; Estonba A; Migliorini P; Czirják L; del Amo J Clin Exp Rheumatol; 2015; 33(5):699-705. PubMed ID: 26314492 [TBL] [Abstract][Full Text] [Related]
38. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920 [TBL] [Abstract][Full Text] [Related]
39. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758 [TBL] [Abstract][Full Text] [Related]
40. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]